Blog

  • Sandra Wagner-Wright’s Gripping New Novella Explores the Cost of Poverty in Colonial Massachusetts

    Sandra Wagner-Wright’s Gripping New Novella Explores the Cost of Poverty in Colonial Massachusetts

    Honolulu, HI October 22, 2025 –(PR.com)– In “The Life & Times of Sarah Good, Accused Witch,” historical fiction author Sandra Wagner-Wright peels back the myth of Salem to reveal a deeper, darker truth: Sarah Good’s real crime wasn’t witchcraft—it was poverty.

    The novella, a prequel to the Salem Stories series, begins in 1672 with two young girls—Sarah Solart Poole Good and Ann Carr Putnam—growing up in comfort in colonial Massachusetts. But their paths quickly diverge. While Ann marries into the powerful Putnam family, Sarah’s life unravels into homelessness and mental instability.

    By 1692, the Putnams’ family fortunes have soured. Disinherited by his father, Thomas Putnam, the Younger, stews in resentment and failure. When his daughter Ann begins to suffer mysterious fits, Putnam seizes the opportunity to protect his daughter while reclaiming his social position. He accuses Sarah Good and two others of practicing witchcraft, and ignites a frenzy of fear in Salem, Massachusetts.

    What follows is a chilling portrait of how insecurity and desperation can twist into vengeance. The witchcraft charge was never about magic—it was rooted in power, driven by fear, and used as a tool to punish the vulnerable.

    This historically grounded narrative has already captivated early readers/critics:

    “Disturbing and historically rich.” —Kirkus

    “…deeply moving and profoundly unsettling. Sandra Wagner-Wright breathes life into one of the most tragic figures of the Salem witch trials…” —Seattle Book Review

    “Wagner-Wright vividly captures the panic and mania that invade Salem, and tragic figures such as Sarah illustrate the power of fear and greed when directed at society’s most vulnerable.” —BookLife by Publishers Weekly

    “…meticulous and fascinating… accessible and endlessly interesting…” —Readers’ Favorite

    As with her previous works, Wagner-Wright draws from original documents and overlooked details to create a fully immersive experience. With a PhD in history and a career spent teaching women’s and global history at the University of Hawai‘i, Wagner-Wright is uniquely positioned to challenge long-held narratives. This is her sixth historical fiction novel.

    Published by Wagner-Wright Enterprises and distributed by Bublish, Inc., “The Life & Times of Sarah Good, Accused Witch” is available now on all major online retailers in eBook ($0.99) and paperback ($14.99). For interviews, review copies, or additional information, please contact Sandra Wagner-Wright at www.sandrawagnerwright.com. To learn more about Bublish and its services, visit www.bublish.com.

    About the Author:
    Sandra Wagner-Wright is an accomplished author of historical fiction, specializing in stories of strong women at pivotal moments in history. She holds a PhD in history and taught at the University of Hawai‘i before turning to writing full time.

    Contact Information:
    Bublish
    Kathy Meis
    843-513-7337
    Contact via Email
    https://bublish.com
    Sandra Wagner-Wright
    https://www.sandrawagnerwright.com/contact/

    Read the full story here: https://www.pr.com/press-release/951803

    Press Release Distributed by PR.com

  • Grisso Launches Clinically-Validated, Precision Probiotic Line Amid Growing Consumer Demand for Science-Backed Wellness Solutions

    Grisso Launches Clinically-Validated, Precision Probiotic Line Amid Growing Consumer Demand for Science-Backed Wellness Solutions

    ONTARIO, CA – October 20, 2025 – PRESSADVANTAGE –

    Grisso, a microbial science company, today announced the launch of its clinically-validated, precision probiotic product line, entering a market increasingly defined by consumer skepticism and demand for clinical validation. The launch comes as the global probiotic supplement market faces mounting criticism over efficacy claims, with consumers expressing frustration over generic formulations that fail to deliver measurable results.

    Grisso products

    Recent industry research indicates that consumer trust in the supplement industry has reached a critical juncture. A growing segment of health-conscious consumers is actively seeking products backed by rigorous clinical evidence rather than marketing claims. This shift in consumer behavior has created an opening for brands that can demonstrate both scientific rigor and manufacturing transparency. Grisso’s entry into this landscape represents a response to what founder Pamela Garcia describes as “the probiotic industry’s trust problem.”

    “Consumers are overwhelmed by vague claims and products that don’t deliver,” Garcia said. “We’re focused on transparency—showing the research, controlling the manufacturing process, and targeting specific health outcomes rather than making broad wellness promises.” This philosophy underpins the company’s product development strategy, which centers on addressing specific health concerns rather than offering general wellness support.

    The company’s initial product portfolio includes G-Serein, formulated to support sleep quality and stress management, G-Sylph, designed specifically for women’s gut health, and G-Serene 4-In-1 Women’s Health Prebiotic + Probiotic, a clinically studied formulation for vaginal health, urinary tract wellness, and yeast balance. Each formulation delivers 100 billion CFU per serving and is built around Weizmannia coagulans BC99, a patented probiotic strain and an international award winner at the 2025 NutraIngredients Awards. The strain has been the subject of multiple clinical studies examining its effects on digestive health, metabolic function, and athletic performance. By centering its product line around a single, extensively researched core ingredient rather than combining multiple strains with limited individual evidence, Grisso aims to offer what it terms “precision probiotic solutions” with clear, targeted biological objectives.

    What distinguishes Grisso’s approach from many competitors is its operational structure. Unlike most supplement brands that rely on contract manufacturers and third-party suppliers, Grisso operates its own integrated research and manufacturing facility. This vertical integration model, more commonly associated with pharmaceutical production than dietary supplements, allows the company to maintain direct oversight of every stage of development and production. From initial strain cultivation through final product testing and packaging, all processes occur under the company’s direct supervision. This end-to-end control structure addresses one of the most significant pain points in consumer trust: the lack of transparency in supplement supply chains.

    Industry observers note that this manufacturing approach, while capital-intensive, may resonate with an increasingly sophisticated consumer base. As wellness consumers become more educated about supplement quality issues, including strain viability, contamination risks, and accurate CFU counts at expiration, brands that can demonstrate comprehensive quality control have a distinct advantage. The facility-ownership model also enables Grisso to conduct proprietary strain research and iterate on formulations based on emerging clinical data, potentially accelerating product development cycles compared to brands dependent on external partners.

    Grisso’s market entry occurs within a competitive landscape that includes established premium probiotic brands such as Seed, Pendulum, and Ritual, all of which have similarly emphasized scientific validation and moved away from generic multi-strain formulations. These brands have collectively helped shift consumer expectations in the category, creating a market segment that prioritizes clinical evidence, strain-specific research, and targeted health outcomes over broad “gut health” claims. Grisso positions itself within this premium tier while differentiating through its manufacturing model and focus on specific condition-based formulations.

    The company is launching with a direct-to-consumer e-commerce model, with its website designed to serve dual functions: product sales and consumer education. Recognizing that its target audience seeks to understand the science behind their wellness choices, Grisso has invested in educational content explaining microbiome science, probiotic mechanisms of action, and the clinical research supporting its formulations. This approach reflects a broader industry trend toward transparency and education as trust-building mechanisms in a category long criticized for opaque marketing practices.

    As the probiotic market continues to mature and regulatory scrutiny of supplement claims intensifies, Grisso’s science-first positioning and vertical integration model represent a bet that the future of the category belongs to brands that can substantiate their claims with both clinical evidence and manufacturing credibility.

    About Grisso: Grisso is a microbial science company specializing in clinically-validated probiotic supplements. The company operates an integrated R&D and manufacturing facility in Ontario, California, and offers targeted formulations for sleep, stress, and women’s health. For more information, visit www.grissolife.com.

    ###

    For more information about Grisso, contact the company here:

    Grisso
    Pamela Garcia
    service@grissolife.com
    DFX MANUFACTORY INC. 1521 S Vineyard Avenue, Ontario, CA 91761, USA

  • Inland Cosmetic Surgery Announces Week of Beauty Patient Appreciation Event

    Inland Cosmetic Surgery Announces Week of Beauty Patient Appreciation Event

    RANCHO CUCAMONGA, CA – October 20, 2025 – PRESSADVANTAGE –

    Rancho Cucamonga-based Inland Cosmetic Surgery announced it will host a “Week of Beauty” patient appreciation event from October 20-24, 2025, featuring both virtual educational sessions and an in-person evening event designed to provide aesthetic treatment education and patient recognition. The week-long program will include daily virtual webinars and conclude with a ticketed appreciation event on Thursday, October 23, 2025.

    Practice director and cosmetic surgeon Dr. Jacob Haiavy, MD, FACS, explained the educational focus behind the event. “This event represents our commitment to patient education and appreciation,” said Dr. Haiavy. “We designed the Week of Beauty to provide comprehensive information about aesthetic treatments while recognizing the trust our patients place in our practice. Patient education has always been fundamental to our approach to aesthetic medicine.”

    The event will begin with virtual educational webinars titled “The Beauty Soirée: Virtual Edition” running Monday through Friday at 12:30 PM and 7:00 PM Pacific Time. These sessions will feature live demonstrations of non-surgical procedures and educational content about aesthetic treatment options available at the practice. The virtual format allows patients throughout the region and beyond to participate regardless of scheduling constraints or geographic location.

    “Patient education remains central to everything we do,” explained Dr. Emma Ryan, DO, who practices alongside Dr. Haiavy at the Rancho Cucamonga facility. “These webinar sessions provide detailed information about treatment processes, patient selection criteria, and realistic expectations for various aesthetic procedures. Our goal is ensuring patients have the comprehensive information needed to make informed decisions about their care.”

    The educational webinars will cover topics including advanced injection techniques, laser therapy applications, and non-surgical body contouring options. Each session will include dedicated time for patient questions and detailed explanations of treatment protocols. The practice’s experienced medical team will present information about safety considerations, recovery timelines, and expected outcomes for various procedures.

    The week will conclude with an in-person Patient Appreciation Event on Thursday, October 23, 2025, from 6:00 PM to 8:00 PM at the practice’s main location at 8680 Monroe Court, Rancho Cucamonga, CA 91730. The ticketed event, priced at $50, will include educational presentations, networking opportunities with the medical team, and a question-and-answer session with both cosmetic surgeons.

    “The in-person event creates an opportunity for direct interaction between patients and our clinical team in a relaxed educational environment,” said Dr. Haiavy. “Attendees will receive detailed information about treatment options, participate in educational discussions, and connect with other patients who share similar aesthetic goals. This personal interaction enhances the educational experience significantly.”

    The evening event will feature refreshments and educational activities designed to inform patients about the latest developments in aesthetic medicine. Attendees will have opportunities to interact with expert injectors and estheticians while learning about advanced treatment techniques and safety protocols in cosmetic procedures.

    Together, Dr. Haiavy, Dr. Ryan, and the Inland Cosmetic Surgery team have performed over 30,000 procedures in a state-of-the-art, fully accredited outpatient surgery center and medical spas. The practice operates multiple locations including associated medical spas Ahava Medspa and Made You Look, serving patients throughout the Inland Empire region of Southern California.

    Inland Cosmetic Surgery has established itself as a regional leader in aesthetic medicine by combining advanced treatment options with comprehensive patient education and personalized care. The practice maintains its commitment to patient safety, natural-looking results, and ongoing education about the latest developments in aesthetic medicine.

    Registration for virtual webinar sessions is available through the practice website, while tickets for the Thursday evening appreciation event are limited and available for purchase online. Those interested in attending either virtual or in-person events can register by visiting the practice website or calling 909-987-0899.

    ###

    For more information about Inland Cosmetic Surgery – Rancho Cucamonga, contact the company here:

    Inland Cosmetic Surgery – Rancho Cucamonga
    Dr. Jacob Haiavy
    909-987-0899
    maryam@inlandcosmetic.com
    8680 Monroe Ct STE 200, Rancho Cucamonga, CA 91730

  • AeroGuard Flight Training Center Partners With U.S. Air Force to Train Future Pilots

    AeroGuard Flight Training Center Partners With U.S. Air Force to Train Future Pilots

    PHOENIX, ARIZONA / ACCESS Newswire / October 22, 2025 / AeroGuard Flight Training Center, a leading provider of flight training with over 25 years’ experience training professional pilots, is excited to announce a new program with the United States Air Force to provide high-quality training for its student pilots. Through this agreement, AeroGuard will provide the initial flight training for Air Force pilots, equipping them with the skills, knowledge, and experience necessary to advance to the next phase of their military aviation careers.

    AeroGuard Selected by U.S. Air Force to Train Future Pilots
    AeroGuard Selected by U.S. Air Force to Train Future Pilots

    Air Force Pilots will train at AeroGuard’s headquarters in Phoenix, Arizona, USA, where they will receive their initial flight training, obtaining their Private Pilot License with Instrument and Multi Engine Ratings. AeroGuard integrates high-quality flight training into every stage of the program, ensuring a smooth transition for pilots to advance to the next phase of their career preparation.

    AeroGuard’s Phoenix, Arizona, campus offers an unparalleled training environment, providing Air Force pilots with 45,000 square feet of campus, over 360 flying days a year, diverse airspace, large standardized fleet, experienced instructors, and expansive practice areas. This ideal flight training environment provides cadets with well-rounded flight experience, instilling the skills they need to become high-quality and confident pilots.

    Joel Davidson, AeroGuard CEO, shared, “AeroGuard is honored and proud to support the United States Air Force in developing its future pilots. Through this partnership, AeroGuard will provide our expertise in initial pilot training for aspiring professional aviators, while the Air Force will receive well-trained pilots fully prepared for their future military roles. Our commitment to safety, excellence, and the highest-quality pilot training seamlessly aligns with the Air Force’s mission, and we look forward to training their student pilots.”

    As a leading flight training provider for airlines and universities across the globe, Air Force pilots at AeroGuard will train in a structured and professional environment, joining future airline pilots from world-leading airlines such as Cathay Pacific, Air New Zealand, and Air India, as well as hundreds of U.S. students training for their own future careers.

    The first class of Air Force Officers is set to start flight training at the end of this month. AeroGuard looks forward to welcoming these officers to campus and preparing them as they grow into successful, skilled, and fully capable pilots for the United States Air Force.

    About AeroGuard Flight Training Center:

    AeroGuard Flight Training Center is a global leader in ab initio flight training with three U.S. campuses that offer accelerated commercial pilot training programs to candidates from all over the world. With a commitment to safety and student success, AeroGuard’s high-quality and career-focused curriculum has established airline-ready cadets for over 25 years with more than one million flight hours of training experience and graduating over 8,000 cadets.

    Contact Information

    James Constable
    Chief Marketing Officer
    jconstable@flyaeroguard.com
    800-322-1526

    .

    SOURCE: Aeroguard Flight Training Center

    View the original press release on ACCESS Newswire

  • Pajar Canada Marks 60 Years With “Zig Zag” Book Chronicling Family Legacy

    Pajar Canada Marks 60 Years With “Zig Zag” Book Chronicling Family Legacy

    Canadian footwear company celebrates six decades as a family-run operation with the publication of a new book

    MONTRÉAL, QC / ACCESS Newswire / October 22, 2025 / Pajar Canada today announced the release of Pajar Zig Zag Book, a new volume that traces the brand’s 60-year path as a family business and its shoemaking roots dating to 1926 in Paris. The book explores the company’s “zigs and zags” through immigration, startup challenges and growth, and how a family built an enterprise kept its focus on purpose, craft, and community.

    Founded in 1963 by Paul Golbert, Pajar takes its name from the first letters of Paul, Jacques, and Rachel. The book follows the family’s immigration to Canada, the opening of the first Montreal showroom, and the launch of in-house manufacturing, while documenting how the brand built products for warmth, protection, and movement in winter conditions.

    “I grew up in this company, learning each part of the craft and sending out the daily mail orders,” said Elise Golbert, chief marketing officer at Pajar Canada and a fifth-generation shoemaker. “Zig Zag is how we tell our story, honestly, with the ups, downs, and family values that continue today.”

    Pajar Zig Zag Book highlights key milestones, including early imports of European footwear to the Canadian market, industry recognition, partnerships on the world stage, and global retail growth. It also outlines the brand’s design process, including materials, construction, and performance testing, as well as the values that continue to guide Pajar: endeavor, loyalty, and passion.

    The book connects the company’s heritage with current collections in performance footwear and outerwear, along with loungewear and cold-weather accessories, showing how the brand’s identity has stayed consistent while evolving with new materials and techniques.

    Pajar Zig Zag Book is available through Pajar Canada’s website and ships via daily mail and parcel carriers.

    For additional information about Pajar, visit and shop, and follow @PajarCanada on Instagram and Facebook and @PajarOuterwear on X (Twitter).

    About Pajar Canada
    Pajar Canada is a fifth-generation family footwear company founded in 1963 and based in Montreal, Quebec. The brand designs, manufactures, wholesales, and retails performance fashion footwear, outerwear, and accessories rooted in a rich handcrafted shoemaking heritage. Collections blend technical materials and craft to deliver warmth, protection, and comfort in cold climates. In 2023, Pajar marked its 60th anniversary with the publication of the Pajar Zig Zag Book, which documents the family’s story and design legacy. Today, the company serves customers globally through e-commerce, retail, and select partners.

    Media contact

    Name: Elise Golbert
    Email: info@pajar.com
    Phone: 1-844-932-1963
    Website: https://ca.pajar.com/

    SOURCE: Pajar Canada

    View the original press release on ACCESS Newswire

  • Geotechnical Drilling Starts at Central Gawler Mill

    Geotechnical Drilling Starts at Central Gawler Mill

    Results to inform detailed TSF1 mine design, schedule and costs

    ADELAIDE, AU / ACCESS Newswire / October 22, 2025 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or the Company) is pleased to confirm that geotechnical drilling has started in support of a recently launched Definitive Feasibility Study for ‘Stage 1′ production (Stage 1 DFS) at the Company’s South Australian Challenger Gold Project (Challenger).1

    The planned program includes 5 sonic drilling holes to recover TSF1 materials for laboratory testing, 24 holes for Cone Penetration Testing (CPTu) and further laboratory testing, and 3 holes for push tube density testing.

    The program is expected to take three weeks to complete, with the results to inform the dry recovery of TSF1 tailings materials, detailed mine design, a mining schedule and estimate of mining costs for the Stage 1 DFS.

    Figure 1 – Cross section showing higher-grade peripheral TSF1 materials & 0.7g/t Au grade shell1

    Commenting on the start of geotechnical drilling, Barton Managing Director Alexander Scanlon said:

    “With the Stage 1 DFS now underway, we are excited to kick off the first of several production-related work programs that will inform key elements of mine design, scheduling, equipment selection and operating costs for tailings recovery.

    “Following a $15m placement led by Franklin Templeton, Barton is well funded to advance the restart of operations at its Central Gawler Mill, with approximately $20m cash in the bank and credit financing discussions underway.

    “We are now on the road to production, leveraging our fully permitted Central Gawler Mill to operations and growth. This is an invaluable stepping stone for our vision to become South Australia’s largest independent gold producer.”

    Authorised by the Managing Director of Barton Gold Holdings Limited.

    For further information, please contact:

    Alexander Scanlon
    Managing Director
    a.scanlon@bartongold.com.au
    +61 425 226 649

    Jade Cook
    Company Secretary
    cosec@bartongold.com.au
    +61 8 9322 1587

    About Barton Gold
    Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.2Moz Au & 3.1Moz Ag JORC Mineral Resources (79.9Mt @ 0.87g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

    Challenger Gold Project

    • 313koz Au + fully permitted Central Gawler Mill (CGM)

    Tarcoola Gold Project

    • 20koz Au in fully permitted open pit mine near CGM

    • Tolmer discovery grades up to 84g/t Au & 17,600g/t Ag

    Tunkillia Gold Project

    • 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources

    • Competitive 120kozpa gold & 250kozpa silver project

    Wudinna Gold Project

    • 279koz Au project located southeast of Tunkillia

    • Significant optionality, adjacent to main highway

    Competent Persons Statement & Previously Reported Information

    The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

    Activity

    Competent Person

    Membership

    Status

    Tarcoola Mineral Resource (Stockpiles)

    Dr Andrew Fowler (Consultant)

    AusIMM

    Member

    Tarcoola Mineral Resource (Perseverance Mine)

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Tarcoola Exploration Results (until 15 Nov 2021)

    Mr Colin Skidmore (Consultant)

    AIG

    Member

    Tarcoola Exploration Results (after 15 Nov 2021)

    Mr Marc Twining (Employee)

    AusIMM

    Member

    Tunkillia Exploration Results (until 15 Nov 2021)

    Mr Colin Skidmore (Consultant)

    AIG

    Member

    Tunkillia Exploration Results (after 15 Nov 2021)

    Mr Marc Twining (Employee)

    AusIMM

    Member

    Tunkillia Mineral Resource

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Challenger Mineral Resource (above 215mRL)

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Challenger Mineral Resource (below 90mRL)

    Mr Dale Sims

    AusIMM / AIG

    Fellow / Member

    Wudinna Mineral Resource (Clarke Deposit)

    Ms Justine Tracey

    AusIMM

    Member

    Wudinna Mineral Resource (all other Deposits)

    Mrs Christine Standing

    AusIMM / AIG

    Member / Member

    The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

    Cautionary Statement Regarding Forward-Looking Information

    This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

    1Refer to ASX announcement dated 29 September 2025

    * Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 8 September 2025. Total Barton JORC (2012) Mineral Resources include 1,049koz Au (39.7Mt @ 0.82 g/t Au) in Indicated category and 1,186koz Au (40.2Mt @ 0.92 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

    SOURCE: Barton Gold Holdings Limited

    View the original press release on ACCESS Newswire

  • Revolve Reports FY2025 Financial Results and Significant Progress on Late-stage Development Projects Across North America

    Revolve Reports FY2025 Financial Results and Significant Progress on Late-stage Development Projects Across North America

    VANCOUVER, BC / ACCESS Newswire / October 22, 2025 / Revolve Renewable Power Corp. (TSXV:REVV)(OTCQB:REVVF) (“Revolve” or the “Company“), a North American owner, operator and developer of renewable energy projects, reported its financial results for the year ended June 30, 2025 (“FY2025”). This earnings release should be read in conjunction with the Company’s consolidated financial statements and management’s discussion and analysis, which are available on the Company’s website at www.revolve-renewablepower.com and have been posted on SEDAR+ at www.sedarplus.ca. All amounts reported are in US dollars.

    “Revolve recorded a 73% increase in recurring revenue from our 13-megawatt (“MW”) portfolio of operating assets while making key investments in the continued development of our project pipeline,” said CEO Myke Clark. “Our team continued to make significant progress on and investments into our pipeline of late-stage development projects with the goal of creating long-term value for shareholders. This revenue model – combining a growing recurring revenue stream with large project development – provides a stable foundation for growth.”

    Key financial highlights (all figures reported in USD)

    • Total recurring revenue from operating assets of $2,241,357, an increase of 73% from recurring revenue of $1,292,297 in FY2024.

    • Total revenue of $3,983,226 for FY2025, compared to total revenue of $6,742,297 in FY2024. The decrease in total revenue is attributable to deferred consideration payments received in FY2024 from the ENGIE Bouse & Parker project sale transaction, which were not a feature of the FY2025 financials.

    • Net loss for FY2025 of $2,590,122, compared to net income of $2,602,510 in FY2024 as the Company continued to make key investments in its portfolio of late-stage development projects.

    • Energy Production of 15,747,489 kWh from operating assets compared to 8,616,916 kWh in FY2024, an increase of 83%.

    • Gross profit of $ 3,238,341, representing a gross profit margin of 81%. Gross profit decreased from $6,386,416 in the comparative period in F2024 due to the decrease in milestone payments from project asset sales.

    • Cash and security deposits on the balance sheet as at June 30, 2025, was $1,950,895.

    Key business highlights

    Develop, Own & Operate – Revolve develops, builds, owns and operates smaller utility scale projects as well as distributed generation projects to generate recurring revenue. This revenue stream, supported by a 13 MW operating portfolio, benefited from the full year impact of the Windriver Power Corporation acquisition in 2024 and the addition of the Colima Distributed Generation (“DG”) project in Mexico. These projects, in addition to the Company’s portfolio of operating DG projects in Mexico, form Revolve’s stable platform for future growth based on long-life, contracted renewable energy assets. Revolve made strong progress on the late stage 20 MW Vernal Battery Energy Storage System (“BESS”) development project in Utah, the 50 MW Primus Wind Project in Colorado and the 15.7 MW Bright Meadows solar project in Alberta, Canada.

    Develop & Sell – Revolve develops large utility scale projects from greenfield to ready-to-build, at which point it sells the development rights to large utilities and independent power producers. The Company has benefited from the proceeds received during FY2023 and FY2024 from the sale of the Bouse & Parker solar and storage projects totaling 1,250 MW to ENGIE, which totalled $6.25m during these periods. Revenues from transactions such as this are difficult to predict in terms of timing and there were no payments received from the ENGIE transaction in FY2025. The Company remains optimistic that the remaining milestone payments from the ENGIE transaction, equating to between $40,000-$50,000 per MW, will be received in future periods.

    During FY2025, the Company also made progress across several other projects in its Develop & Sell portfolio, in particular over 500MW of wind projects in Mexico. The Company’s decision to continue to invest in the development of these projects during FY2025 has placed the company in a good position as the Mexican government ramps up private sector investment in the renewable energy sector. By holding these assets through key de-risking milestones, Revolve is positioned to benefit from enhanced project valuations and a stronger overall portfolio that aligns with the Company’s long-term growth strategy. The Company continues to actively review and consider partnership and monetisation opportunities for these projects. Revolve also completed the sale of the Afton Solar & Storage project during the period, which was an early stage development project in the US.

    During FY2025 and subsequent to the fiscal year-end, Revolve completed several transactions and achieved multiple project milestones across its development portfolio:

    • Revolve Expands Mexico Distributed Generation Business with New Partnership. On October 9, 2025, Revolve announced it has signed a partnership agreement dated October 8, 2025 with an experienced Engineer, Procure and Construct company (the “EPC Partner”) in Mexico to develop and build a new portfolio of distributed generation power solutions for commercial and industrial customers, targeting two initial portfolios of commercial projects totaling more than 5 MW of capacity. The EPC Partner has previously developed more than 50 MW of distributed generation solar projects and brings valuable expertise to the partnership.

    • Revolve Receives Approval from the Alberta Utilities Commission for the 15.7 MW Bright Meadows Solar Project. On September 15, 2025, Revolve, announced that its wholly-owned subsidiary, Revolve Meadows Solar GP Inc., has received Power Plant Approval (Decision 29985-D01-2025) from the Alberta Utilities Commission (“AUC”) Bright Meadows Solar Project (“Bright Meadows Project”). Located in in the County of Wetaskiwin, Alberta, approximately 80 km south of Edmonton, the Bright Meadows Project is a 15.7 MW solar power project that will generate enough renewable electricity to power more than 3,700 homes once operational. AUC approval is the key regulatory permit required for the Bright Meadows Solar Project and we are now moving forward on the final interconnection and construction planning for this project. Revolve would like to thank the County of Wetaskiwin, the local community and our partners for their support through the AUC process.

    • Revolve Signs Agreement to Acquire 30 MWp Solar Project in Canada. As announced on September 22, 2025, the Company has entered into a binding Letter of Intent (“LOI”) to acquire the assets related to the Project and will enter into an asset transfer agreement (“ATA”), subject to certain customary closing conditions. Following the AUC permit approval for the Company’s 15.7 MW Bright Meadows solar project, the Company has moved to secure a further late-stage development project in the province. The current intention is to have the Bright Meadows project ready to build and under construction in 2026, which will be followed by this 30 MWp project in 2027 creating a consistent pipeline of ‘Develop and Build’ projects in Canada.

    • CHP Project Asset Sale Transaction. On February 18, 2025, the Company announced the sale of a 3 MW combined heat and power project (the “CHP Project”) from its distributed generation portfolio for total cash consideration of $1.5 million. The CHP Project was originally acquired by Revolve in August 2022 as part of the $1.4m acquisition of Centrica Business Solutions Mexico S.A. de C.V. Revolve regularly assesses its assets to determine optimal capital allocation – in the case of the CHP Project, the Company took the opportunity to monetize this asset and reinvest that capital into higher return near-term opportunities.

    The Company also announces the grant of Deferred Share Units (“DSUs”) to Company directors effective October 22, 2025. A total of 401,585 DSU’s have been granted under the Company’s Deferred Share Unit Plan adopted on July 6, 2022. Each DSU entitles the holder to receive one share of the Company, or in certain circumstances a cash payment equal to the value of one share of the Company, at the time the holder ceases their position with the Company. The DSUs vest one year from the date of grant. The DSUs were granted for Q4 F2025 at a price of C$0.23 per share. The Company issues DSUs at the end of each quarter in lieu of cash director’s fees to preserve working capital for project development initiatives.

    For further information contact:
    Myke Clark, CEO
    IR@revolve-renewablepower.com
    778-946-0072

    About Revolve
    Revolve was formed in 2012 to capitalize on the growing global demand for renewable power. Revolve develops utility-scale wind, solar, hydro and battery storage projects in the US, Canada and Mexico. Revolve also installs and operates sub 20MW “behind the meter” distributed generation (or “DG”) assets. Revolve’s portfolio includes the following:

    • Operating Assets: 13 MW (net) of operating assets under long term power purchase agreements across Canada and Mexico covering wind, solar, battery storage and hydro generation;

    • Development: a diverse portfolio of utility scale development projects across the US, Canada and Mexico with a combined capacity of over 3,000MWs as well as a 140MW+ distributed generation portfolio that is under development.

    Revolve has an accomplished management team with a demonstrated track record of taking projects from “greenfield” through to “ready to build” status and successfully concluding project sales to large operators of utility-scale renewable energy projects. To-date, Revolve has developed and sold over 1,550MW of projects.

    Going forward, Revolve is targeting 5,000MW of utility-scale projects under development in the US, Canada and Mexico, and in parallel is rapidly growing its portfolio of revenue-generating DG assets.

    Forward Looking Information
    The forward-looking statements contained in this news release constitute ‘‘forward-looking information” within the meaning of applicable securities laws in each of the provinces and territories of Canada and the respective policies, regulations and rules under such laws and ‘‘forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (collectively, ‘‘forward-looking statements”). The words “will”, “expects”, “estimates”, “projections”, “forecast”, “intends”, “anticipates”, “believes”, “targets” (and grammatical variations of such terms) and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company’s project development and construction timelines, regulatory approvals, asset acquisitions and sales, strategic partnerships, expected energy production, and the advancement and monetization of its project pipeline. This forward-looking information and other forward-looking information are based on our opinions, estimates and assumptions considering our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Material factors underlying forward-looking information and management of the Company’s (“Management“) expectations include: the receipt of applicable regulatory approvals; the absence of material adverse regulatory decisions being received and the expectation of regulatory stability; the absence of any material equipment breakdown or failure; availability of financing on commercially reasonable terms and the stability of credit ratings of the Company and its subsidiaries; the absence of unexpected material liabilities or uninsured losses; the continued availability of commodity supplies and stability of commodity prices; the absence of interest rate increases or significant currency exchange rate fluctuations; the absence of significant operational, financial or supply chain disruptions or liability, including relating to import controls and tariffs; the continued ability to maintain systems and facilities to ensure their continued performance; the absence of a severe and prolonged downturn in general economic, credit, social or market conditions; the successful and timely development and construction of new projects; the absence of capital project or financing cost overruns; sufficient liquidity and capital resources; the continuation of long term weather patterns and trends; the absence of significant counterparty defaults; the continued competitiveness of electricity pricing when compared with alternative sources of energy; the realization of the anticipated benefits of the Company’s acquisitions and joint ventures; the absence of a change in applicable laws, political conditions, public policies and directions by governments, materially negatively affecting the Company; the ability to obtain and maintain licenses and permits; maintenance of adequate insurance coverage; the absence of material fluctuations in market energy prices; the absence of material disputes with taxation authorities or changes to applicable tax laws; continued maintenance of information technology infrastructure and the absence of a material breach of cybersecurity; the successful implementation of new information technology systems and infrastructure; favourable relations with external stakeholders; our ability to retain key personnel; our ability to maintain and expand distribution capabilities; and our ability to continue investing in infrastructure to support our growth.

    These and other uncertainties and risks could cause actual results to differ materially from those expressed or implied by the forward-looking statements or to cause the underlying assumptions to prove incorrect. Such uncertainties and risks may include, among others, market conditions, delays in obtaining or failure to obtain required regulatory approvals in a timely fashion, or at all; the availability of financing, fluctuating prices, the possibility of project cost overruns, mechanical failure, unavailability of parts and supplies, labour disturbances, interruption in transportation or utilities, adverse weather conditions, and unanticipated costs and expenses, variations in the cost of energy or materials or supplies or environmental impacts on operations, disruptions to the Company’s supply chains; changes to regulatory environment, including interpretation of production tax credits; armed hostilities and geopolitical conflicts; risks related to the development and potential development of the Company’s projects; conclusions of economic evaluations; changes in project parameters as plans continue to be refined; the availability of tax incentives in connection with the development of renewable energy projects and the sale of electrical energy; as well as those factors discussed in the sections relating to risk factors discussed in the Company’s continuous disclosure filings on SEDAR+ at sedarplus.ca. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates.

    Future-oriented financial information (“FOFI“) and financial outlooks contained in this release, including statements regarding estimated capital expenditures, anticipated milestone payments, and projected financial outcomes from project sales or partnerships and, are provided for illustrative purposes only and are subject to the same assumptions, risk factors, and uncertainties described above with respect to forward-looking information. Such FOFI reflects Management’s current estimates and assumptions considered reasonable in the circumstances, which may prove incorrect. Actual financial results may differ materially from Management’s expectations, and such variations may be material and adverse. The Company’s financial projections are inherently speculative, were not prepared with a view toward compliance with applicable GAAP and have not been reviewed or audited by independent accountants or other third-party experts, and should not be relied upon as indicative of future results. Such information is presented for illustrative purposes only and may not be an indication of our actual financial position or results of operations.

    Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements or FOFI to reflect new information, subsequent or otherwise. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements or FOFI whether because of new information, future events or otherwise, except as required by law.

    “Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

    SOURCE: Revolve Renewable Power Corp.

    View the original press release on ACCESS Newswire

  • SMX Tightens Its Core as the World Moves Toward Its Proof-Based Economy (NASDAQ: SMX)

    SMX Tightens Its Core as the World Moves Toward Its Proof-Based Economy (NASDAQ: SMX)

    NEW YORK, NY / ACCESS Newswire / October 22, 2025 / Every investor knows the reflex. You see the words reverse split, and your instincts flinch. It’s practically Pavlovian. But sometimes, what looks like retreat is actually recalibration. And that’s exactly what’s happening at SMX (NASDAQ:SMX). The company that made “proof” a product and traceability a trillion-dollar opportunity just tightened its capital structure in a move that could position it for an entirely different kind of growth.

    As of October 23, 2025, SMX’s recap will take effect, consolidating approximately 15.5 million ordinary shares into about one million. The math may look surgical, but the intent is strategic. This isn’t a desperate act of survival; it’s a precision tune-up for a company that’s been quietly building the digital backbone of global commerce.

    Re-engineering the Foundation

    Let’s cut through the noise. A reverse split doesn’t change a company’s fundamentals. What it does change is perception-and for SMX, perception has always been a powerful asset. The move tightens the float, raises the share price, and signals confidence that the company’s valuation story is far from over. It’s the kind of restructuring that clears static from the air, giving the real story room to breathe.

    That story, by the way, is massive. SMX’s molecular marker technology is redefining authenticity, transforming physical goods into verifiable digital assets-proof instead of promise. Whether it’s plastics, metals, textiles, or electronics, the company’s system can permanently encode a material’s origin, lifecycle, and legitimacy.

    This isn’t theory; it’s traction. SMX’s ecosystem already includes partnerships with Singapore’s A*STAR, CETI in France, Tradepro Group, BT-Systems and REDWAVE in Europe, NAFRA and AsureQuality in Australia, and even collaborative initiatives extending into defense and critical minerals supply chains. Add to that its ongoing work with BASF and Continental, and you begin to see a network that’s not just expanding, but compounding in influence. SMX isn’t just participating in global traceability-it’s defining it.

    While others react to regulation, SMX is quietly building the infrastructure regulators will rely on. That’s not survival-it’s strategy.

    A Cap Structure Built for Momentum

    So why consolidate now? Because timing is everything. The reduction in outstanding shares creates a leaner, more investable structure-one that institutions can actually take a position in without tripping over penny-stock stigma. It’s also the first real sign that management is thinking two moves ahead, not just about survival, but about scalability.

    SMX’s balance sheet now looks like a spring-loaded platform: compact, simplified, and ready for lift. With fewer shares on the table, each incremental achievement-new project, new geography, new validation-will have a more meaningful impact on per-share value. It’s the market’s equivalent of tightening your core before the next climb.

    Proof Still Pays

    Investors who’ve been around long enough know that markets often misread these moments. They see consolidation as contraction. In reality, it’s preparation. SMX isn’t trying to look bigger; it’s getting stronger. Its partnerships are multiplying across continents, its Plastic Cycle Token is evolving into the value layer of circular commerce, and its proof-based verification model is becoming the global standard for sustainability.

    Reverse split or not, the business trajectory is unmistakable: up.

    SMX has always been about transforming invisible data into visible truth-and now, it’s doing the same with its capital structure. What investors should see isn’t a shrinking chart, but a sharpening silhouette. Because when the foundation is this strong, consolidation isn’t a warning sign. It’s the prelude to acceleration.

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements

    The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

    EMAIL: info@securitymattersltd.com

    SOURCE: SMX (Security Matters) Public Limited

    View the original press release on ACCESS Newswire

  • Spine Surgeon Dr. John Peloza Shared Insights on Leading a Single-Specialty ASC at Becker’s 31st Annual Meeting

    Spine Surgeon Dr. John Peloza Shared Insights on Leading a Single-Specialty ASC at Becker’s 31st Annual Meeting

    Founder of Peloza Spine joined national healthcare leaders to discuss physician-led innovation and operational excellence in orthopedic ambulatory surgery centers.

    CHICAGO, IL / ACCESS Newswire / October 22, 2025 / John H. Peloza, MD, founder of Peloza Spine in Chesterfield, Missouri, was among the featured speakers at the Becker’s 31st Annual ASC Meeting: The Business and Operations of ASCs, which took place October 16-18, 2025, at the Swissôtel Chicago. Dr. Peloza joined a distinguished panel of orthopedic leaders in the session titled “How to Lead a Single-Specialty Orthopedic ASC.”

    The discussion examined how single-specialty orthopedic ASCs have evolved beyond efficiency to become strategic hubs for growth, innovation, and physician alignment. Panelists shared insights on expanding complex case capabilities, navigating payer friction, optimizing the patient journey, and adopting technology to strengthen outcomes and sustainability.

    Drawing on his experience advancing motion-preserving spine surgery, Dr. Peloza described how surgical innovation and ASC operations needed to evolve together. He noted that the same principles driving efficiency such as team coordination, patient education, and outcome tracking were essential to supporting advanced spine procedures in an outpatient environment.

    “The ASC model has redefined how we deliver orthopedic and spine care,” said Dr. Peloza. “When physicians lead these centers, we can make nimble, data-informed decisions that enhance outcomes, expand access, and align care directly with patient needs. For spine, that means investing in teams, workflows, and technology that make motion-preserving and minimally invasive procedures truly feasible in an outpatient setting.”

    Joining Dr. Peloza on the panel were LoAnn Vande Leest, RN, MBA-H, CNOR, CASC, Executive Director of The Orthopaedic Surgery Center; Dave Fitzgerald, Chief Executive Officer of OrthoNY; and Jonathan Brown, MD, Board Member of U.S. Orthopaedic Partners and Orthopedic Surgeon at Bienville Orthopaedic Specialists. The session was moderated by Kelly Gooch, Senior Editor and Enterprise Lead at Becker’s Healthcare.

    Becker’s 31st Annual ASC Meeting brought together more than 4,000 surgery center and hospital leaders from across the United States to discuss the most pressing trends in healthcare business and operations. Sessions covered topics ranging from payer contracting and technology adoption to physician alignment and value-based care. For more information about the event, visit https://conferences.beckershospitalreview.com/31st_Annual_ASC_Meeting_2025.

    Dr. Peloza is available for interviews to discuss physician-led ASC models, motion preservation spine surgery, and the future of outpatient orthopedic care.

    About Dr. John Peloza

    Dr. John Peloza is a nationally recognized orthopedic spine surgeon with more than three decades of experience advancing motion preservation, minimally invasive spine surgery, and biologic disc repair. A prolific clinical researcher and innovator, he has served as principal investigator in 10 FDA-regulated trials and over two dozen randomized trials. Dr. Peloza holds 16 patents in spinal device and procedural technologies. Dr. Peloza is widely regarded as a pioneer in artificial disc replacement and has trained hundreds of surgeons in motion-preserving techniques. His work integrates clinical precision with a deep commitment to improving outcomes and quality of life for patients with complex spinal disorders.

    About Peloza Spine

    Peloza Spine is a specialty spine care center located within Midwest Orthopedic and Spine Specialists in Missouri, founded by Dr. John Peloza. The practice is dedicated to advancing the next generation of spinal care through a patient-centric approach that emphasizes motion preservation, surgical precision, and biologic disc regeneration. Peloza Spine provides comprehensive diagnostic services, non-operative solutions, and a full range of surgical options – including artificial disc replacement, fusion revision, and minimally invasive procedures. With a focus on restoring function and avoiding unnecessary fusion, Peloza Spine helps patients regain motion, reduce pain, and return to active living.

    Media Contact:

    Brandi Kamenar
    Brandi Kamenar Brand Management
    Email: brands@brandikamenar.com
    Phone: (310) 734-6180

    SOURCE: Peloza Spine

    View the original press release on ACCESS Newswire

  • Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

    Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

    Company to discontinue development of mRNA-1647 in congenital CMV

    Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients

    Company does not anticipate any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028

    CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s investigational cytomegalovirus (CMV) vaccine. The study did not meet its primary efficacy endpoint of preventing CMV infection in seronegative female participants of childbearing age (16-40 years of age). Moderna will discontinue its congenital CMV clinical development program.

    “Today’s announcement is disappointing for families and healthcare professionals who have been eagerly awaiting a CMV vaccine to prevent congenital CMV, a leading infectious cause of birth defects,” said Stéphane Bancel, Chief Executive Officer of Moderna. “The majority of the data from this trial is still forthcoming, and we will share our full results with the scientific community in hopes that our learnings can contribute to the continued pursuit of a CMV vaccine. I am grateful for our dedicated team, our partners at clinical trial sites, and all the trial participants who made this research possible.”

    The Phase 3 trial (NCT05085366) was a randomized, observer-blind, placebo-controlled study. The study included approximately 7,500 women 16-40 years of age from approximately 300 sites across 13 countries, representing the largest trial assessing the efficacy of a CMV vaccine to-date. Vaccine efficacy against primary CMV infection in healthy women was well below the Company’s target, ranging from 6% to 23% depending on the case definition used.

    “We are clearly disappointed by the failure to prevent primary infection because it means there is still no vaccine for the prevention of congenital CMV despite the many decades of work by the field,” said Stephen Hoge, MD, President of Moderna. “CMV does cause significant disease in other contexts, including reactivation of the latent virus in those undergoing bone marrow transplantation, and we will continue to explore the potential of mRNA-1647 to suppress disease associated with reactivation in those high-risk patients through our ongoing Phase 2 study.”

    mRNA-1647 was found to be generally well-tolerated regardless of CMV serostatus, with a safety profile consistent with earlier studies. No safety concerns have been raised by the Data and Safety Monitoring Board. The Company plans to continue its study of mRNA-1647 in bone marrow transplant patients, which is currently in a Phase 2 trial (NCT05683457).

    Moderna does not anticipate any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028. Moderna anticipated minimal initial revenue contribution from mRNA-1647 given necessary investments in market building and launch, and expected the product to be cash-flow negative in 2028.

    About Moderna

    Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.

    Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s 2025 financial guidance and its expectation of achieving breakeven in 2028; and the potential of mRNA-1647 for bone marrow transplant patients and Moderna’s ongoing Phase 2 trial. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

    Moderna Contacts

    Media:

    Chris Ridley
    Head of Global Media Relations
    +1 617-800-3651
    Chris.Ridley@modernatx.com

    Investors:

    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    +1 617-209-5834
    Lavina.Talukdar@modernatx.com

    SOURCE: Moderna, Inc.

    View the original press release on ACCESS Newswire